Track OACC and 10,000+ stocks
Create a free account to build watchlists, compare peers, and value any stock.
- Build and track watchlists
- Compare against peers
- Earnings & price alerts
No credit card required
Main
Market Cap$263.28M
Enterprise Value$261.86M
Revenue (TTM)-
Net Income (TTM)$7.29M
Free Cash Flow (TTM)-$407.95K
Financial Health
Cash$1.43M
Net Debt-$1.42M
Debt Ratio0
Debt to Equity0
Interest Coverage-
Valuation (TTM)
Price to Sales-
Price to Earnings36.12
EV to EBITDA288.42
Price to Book1.35
Price to Free Cash Flow-645.38
Margins (TTM)
Gross Profit Margin-
EBITDA Margin-
Operating Income Margin-
Net Income Margin-
Free Cash Flow Margin-
Returns (5Y Avg)
Return on Invested Capital-
Return on Assets-
Return on Equity-
Return on Total Capital-
Return on Capital Employed-
Dividend Summary
Dividend Yield-
Annual Dividend-
Payout Ratio-
Ex Dividend Date-
5-Year Dividend CAGR-
CAGR (5Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (3Y)
Revenue-
Diluted EPS-
Total Debt-
Capital Expenditures-
Free Cash Flow-
CAGR (1Y)
Revenue0.00%
Diluted EPS1000.00%
Total Debt0.00%
Capital Expenditures-75.00%
Free Cash Flow-100.00%
$10.71+$0.01|+0.09%
52W High$10.74
52W Low$10.30
50D SMA$10.68
200D SMA$10.63
Volume52.90K
Oaktree Acquisition Corp. III Life Sciences Class A Ordinary Share
333 South Grand Avenue, Los Angeles, CA, United States, 90071
IPO
2024
Employees
0
Industry
Shell Companies
Sector
Financial Services
Oaktree Acquisition Corp. III Life Sciences does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. It intends to target companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors in North America and Europe. The company was founded in 1995 and is headquartered in Los Angeles, California.
Insider Transactions
Quarterly buy vs. sell activity
No insider transactions data available for this period
Analyst Ratings
No coverage data
No analyst ratings data available